Claim Missing Document
Check
Articles

Found 2 Documents
Search

Eksplorasi Faktor-Faktor Penentu Niat Kepatuhan Pengobatan pada Pasien Diabetes Melitus Tipe 2: Studi dengan Pendekatan Theory of Planned Behavior pada Masyarakat Jawa Fransiska Indah Pratiwi; Aris Widayati; Pramitha Esha Nirmala Dewi
Jurnal Ilmiah Medicamento Vol 12 No 1 (2026): Jurnal Ilmiah Medicamento (In progress)
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v12i1.12680

Abstract

Background: Diabetes mellitus (DM) requires long-term therapy, which may reduce patients’ adherence to medication and ultimately lead to treatment failure.Objective: This study aimed to analyze factors influencing medication adherence intention among patients with type 2 diabetes mellitus (T2DM) based on the Theory of Planned Behavior (TPB).Methods: An analytical observational study with a cross-sectional design was conducted among patients diagnosed with T2DM in Purworejo Regency, Central Java. Data was collected using a structured questionnaire and analyzed using binary logistic regression in SPSS version 25. A total of 382 respondents were included in the analysis.Results: Most participants were female, aged 55–65 years, employed, and had an elementary school education or equivalent. The proportion of respondents with high medication adherence intention was 85.9%. Attitude, subjective norm, and perceived behavioral control jointly explained 53.6% of the variance in medication adherence intention. Among these variables, subjective norm demonstrated the strongest association with adherence intention (OR = 197.019; p < 0.001).Conclusion: These findings suggest that social influence, particularly encouragement and support from family members and healthcare providers, plays a dominant role in shaping medication adherence intention within a collectivist socio-cultural setting. Integrating culturally sensitive, family-centered approaches into diabetes management programs may therefore strengthen adherence intention and improve long-term treatment outcomes among patients with T2DM.
Analisis Biaya Pengobatan Asma Anak Pada Pasien Rawat Jalan di Rumah Sakit Pemerintah di Yogyakarta Berdasarkan Tarif INA-CBG's Tahun 2023 Ingenida Hadning; Muhammad Aqil Faiq Akbar; Aris Widayati
Journal of Pharmaceutical and Sciences JPS Volume 9 Nomor 2 (2026)
Publisher : Fakultas Farmasi Universitas Tjut Nyak Dhien

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36490/journal-jps.com.v9i2.1630

Abstract

Introduction: Asthma is one of the most common chronic respiratory diseases in children, affecting daily activities, growth, and quality of life. Recurrent treatment imposes a considerable economic burden on families and healthcare providers. The Indonesian government implements the Indonesian Case-Based Groups (INA-CBG) payment system within the National Health Insurance (JKN) program to control healthcare costs. Objective: This study aimed to analyse direct medical costs and evaluate the conformity between actual treatment costs and INA-CBG tariffs in 2023 for pediatric outpatient asthma patients at a public hospital in Yogyakarta. Methods: An observational retrospective study was conducted using medical records and cost data of pediatric asthma outpatients at RS Paru Respira Yogyakarta from January 2024 to September 2025. Samples were selected through total sampling based on inclusion and exclusion criteria. Descriptive analysis was used to calculate direct medical costs, while conformity with INA-CBG tariffs was analysed using a one-sample t-test and a Wilcoxon test. Results: A total of 79 patients with 290 outpatient visits were analysed. The average actual costs were Rp248,953 for Q-5-44-0 (n=243), Rp383,490 for J-3-13-0 (n=28), and Rp406,506 for J-3-16-0 (n=19). Medication costs accounted for the largest component (42-52%). Significant differences were found between actual costs and INA-CBG tariffs for all codes (p<0.05). Actual costs exceeded tariffs for codes Q-5-44-0 and J-3-13-0 but were lower for code J-3-16-0. The total negative difference reached Rp14,282,904. Conclusion: There is a significant discrepancy between actual treatment costs and INA-CBG tariffs for pediatric outpatient asthma care in 2023. Medication costs represent the largest component of treatment expenditures. These findings indicate the need for continuous evaluation of the INA-CBG payment system and healthcare cost management strategies to improve efficiency while maintaining service quality.